Open AccessSafety Profile and Clinical Recommendations for the Use of Lapatinib
Author(s) -
D. Chatsiproios
Publication year - 2010
Publication title -
breast care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.767
H-Index - 30
eISSN - 1661-3805
pISSN - 1661-3791
DOI - 10.1159/000285776
Subject(s) - lapatinib , medicine , rash , tyrosine kinase inhibitor , toxicity , tyrosine kinase , pharmacology , epidermal growth factor receptor , oncology , receptor , trastuzumab , cancer , breast cancer
SUMMARY: The toxicity profile of agents blocking the epidermal growth factor receptor pathway excludes many of the severe side effects commonly observed with cytotoxic chemotherapy. Like other tyrosine kinase inhibitors, lapatinib is generally well tolerated. Lapatinib exhibits specific toxicities, the most common being diarrhea and rash, which are mostly mild to moderate in severity. Cardiac toxicity is rarely seen with lapatinib. Generally, lapatinib-associated toxicities are manageable.